Document text
Principal Investigator: Xiangming Ji
Organization: EPIC NUTRITION FOR Y LLC
Fiscal Year: 2024
Award: $194,275
Funding agency: National Institute of Diabetes and Digestive and Kidney Diseases
PROJECT SUMMARY/ABSTRACT:
Obesity is a major public health problem in the United States. It is linked to insulin resistance and type 2
diabetes, two devastating diseases that affect millions of Americans. Current treatments for obesity have
largely failed to achieve long-term success, highlighting the need for new, long-term sustainable strategies.
Our goal is to develop a preventive and complementary nutritional intervention for obesity and its associated
insulin resistance that is non-invasive, long-lasting, and low-cost. We are particularly interested in the potential
of Clostridium cochlearium 2316 (CC), a proprietary bacterial strain that has demonstrated significant and
consistent activities in reducing obesity and insulin resistance. CC is a spore-forming anaerobic bacterium that
has been found in the gut of many mammals, including humans. Unlike certain known pathogenic Clostridium
species, CC is considered safe for humans, as it is classified as a Biological Safety Level (BSL)-1 bacterium.
Our preliminary studies have illuminated CC's potential. Dietary supplementation with CC led to substantial
alterations in the gut microbiome and resulted in a 22% reduction in body weight gain among high-fat diet-
induced obese (DIO) mice, all without impacting food intake. Moreover, CC intake led to a significant 47%
reduction in insulin resistance and complete restoration of glucose homeostasis in obese mice. Notably, CC
displayed no toxicity, and no traces of antibiotic-resistant genes or virulence factors were detected. These
consistent findings substantiate the potential nutraceutical application of CC in obesity management. In this
Phase I proposal, we are seeking support for critical toxicity and safety assessments of CC for long-term
dietary interventions, as mandated for IND-required studies preceding clinical trials. Specifically, our aims are
twofold: Aim 1: To elucidate the pharmacokinetics and pharmacodynamics of acute CC ingestion in DIO mice,
a crucial step towards ensuring the safe and effective use of CC. Aim 2: To determine the long-term efficacy
and safety of CC treatment in mitigating obesity and insulin resistance in DIO mice. These findings hold utmost
importance as they set the stage for subsequent transformative research endeavors in clinical evaluation.
Following the confirmation of its long-term safety and efficacy in this study, CC is poised to pursue FDA
Generally Recognized as Safe (GRAS) status. Such a designation would enable CC's inclusion as a food
ingredient or additive within legal bounds, thereby enabling its formulation as a dietary supplement. Our study
will open a new avenue using a novel probiotic as a safe, low cost, and long-term sustainable dietary
supplement/medical food for obesity management. This study is significant because it will not only provide
mechanistic insights into how CC reduces diet-induced obesity, but will also provide long-term safety and
efficacy data to be readily used for clinical trials to further confirm its effects on obesity and metabolic
outcomes, which if shown to be efficacious, would have an immediate and strong impact on public health given
the obesity epidemic in the United States.
Terms: <Acute><Address><Adherence><Adult-Onset Diabetes Mellitus><Adverse effects><Affect><Alimentary Canal><American><Anaerobic Bacteria><Antibiotic Resistance><Bacteria><Bile Acids><Binding><Biological><Blood Plasma><Body Tissues><Body Weight><Body fat><Chronic><Classification><Clinical><Clinical Evaluation><Clinical Testing><Clinical Trials><Clostridium><Colon><Consumption><Data><Development><Diabetes Mellitus><Dietary Intervention><Dietary Supplementation><Digestive Tract><Disease><Disorder><Dose><Drug Kinetics><Drugs><Eating><Energy Expenditure><Energy Metabolism><Ensure><Environment><Epidemic><Evaluation><Excretory function><Food><Food Intake><Food Supplements><Formulation><Future><GI Tract><GI microbiome><GI microbiota><Gastrointestinal Tract><Gastrointestinal microbiota><Gastrointestinal tract structure><Goals><Guidelines><High Fat Diet><Human><Ingestion><Insulin Resistance><Intake><Investigation><Investigational Drugs><Investigational New Drugs><Ketosis-Resistant Diabetes Mellitus><Laboratories><Legal><Legal patent><Link><Literature><Liver><Mammalia><Mammals><Maturity-Onset Diabetes Mellitus><Medication><Medicine><Metabolic><Mice><Mice Mammals><Modern Man><Modification><Molecular Interaction><Monitor><Murine><Mus><NIDDM><Non-Insulin Dependent Diabetes><Non-Insulin-Dependent Diabetes Mellitus><Noninsulin Dependent Diabetes><Noninsulin Dependent Diabetes Mellitus><Nutraceutical><Nutrition Interventions><Nutritional Interventions><Obese Mice><Obesity><Obesity Epidemic><Organism><Outcome><PK/PD><Patents><Pathogenicity><Pathogenicity Factors><Pharmaceutical Preparations><Pharmacodynamics><Pharmacokinetics><Phase><Plasma><Plasma Serum><Pre-Clinical Model><Preclinical Models><Preventive><Probiotics><Public Health><Publications><Reducing diet><Regulatory Pathway><Reproduction spores><Research><Resistance to antibiotics><Resistant to antibiotics><Reticuloendothelial System, Serum, Plasma><Risk><Rodent><Rodentia><Rodents Mammals><Safety><Scientific Publication><Short-Chain Fatty Acids><Site><Slow-Onset Diabetes Mellitus><Spores><Stable Diabetes Mellitus><Structure><Systematics><T2 DM><T2D><T2DM><Therapeutic><Time><Tissues><Toxic effect><Toxicities><Type 2 Diabetes Mellitus><Type 2 diabetes><Type II Diabetes Mellitus><Type II diabetes><United States><Virulence Factors><Volatile Fatty Acids><Weight Gain><Weight Increase><Weight maintenance regimen><absorption><adiposity><adult onset diabetes><alimentary tract><anaerobe><antibiotic drug resistance><antibiotic resistant><biologic><blood glucose regulation><body weight gain><body weight increase><clinical test><commensal bacteria><commensal bacterial species><corpulence><cost><determine efficacy><developmental><diabetes><diet intervention><diet supplement><diet supplementation><diet-associated obesity><diet-induced obesity><diet-related obesity><dietary><dietary supplements><digestive canal><digestive tract microbiome><drug/agent><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><enteric microbial community><enteric microbiome><enteric microbiota><evaluate efficacy><examine efficacy><excretion><gastrointestinal microbial flora><gastrointestinal microbiome><glucose control><glucose homeostasis><glucose regulation><glucose tolerance><gut commensal><gut community><gut flora><gut microbe community><gut microbial community><gut microbial composition><gut microbial consortia><gut microbiome><gut microbiota><gut microbiotic><gut microflora><gut-associated microbiome><hepatic body system><hepatic organ system><in vivo><ingest><innovate><innovation><innovative><insight><insulin resistant><insulin sensitivity><insulin tolerance><interest><intestinal biome><intestinal flora><intestinal microbiome><intestinal microbiota><intestinal microflora><intestinal tract microflora><ketosis resistant diabetes><living system><maturity onset diabetes><medical food><novel><nutritional approach><nutritional supplement><ob/ob mouse><obesity development><obesity intervention><obesity management><obesity therapy><obesity treatment><pharmacokinetics and pharmacodynamics><pharmacologic><pre-clinical><pre-clinical toxicity><preclinical><preclinical toxicity><prevent><preventing><product development><protective effect><research clinical testing><resistance gene><resistance locus><resistant gene><restoration><safety assessment><success><type 2 DM><type II DM><type two diabetes><weight control><weight management><wt gain>